LOGIN  |  REGISTER
Astria Therapeutics

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 557.18
1.66 0.30
677,906
382.50M
US$ 213.120B
US$ 235.09
-4.79 -2.00
1.23M
722.28M
US$ 169.800B
US$ 141.53
5.43 3.99
392,111
285.60M
US$ 40.420B
US$ 199.25
-5.39 -2.63
746,098
181.50M
US$ 36.160B
US$ 415.27
-7.35 -1.74
60,549
81.88M
US$ 34.000B
US$ 77.88
-1.96 -2.45
725,930
390.60M
US$ 30.420B
US$ 1.00
-7.31 -0.58
30,905
21.10M
US$ 26.580B
US$ 397.01
-2.86 -0.72
162,570
59.38M
US$ 23.570B
US$ 144.13
-0.09 -0.06
1.01M
158.60M
US$ 22.860B
US$ 166.75
-2.55 -1.51
312,521
132.02M
US$ 22.010B
US$ 229.94
-4.16 -1.78
117,050
83.64M
US$ 19.230B
US$ 151.14
-2.88 -1.87
121,640
111.62M
US$ 16.870B
US$ 203.11
-14.88 -6.83
1.11M
82.56M
US$ 16.770B
US$ 120.48
-2.22 -1.81
134,331
121.70M
US$ 14.660B
US$ 332.06
-19.95 -5.67
152,881
31.08M
US$ 10.320B
US$ 55.05
-3.46 -5.91
888,742
185.08M
US$ 10.190B
US$ 45.46
-0.54 -1.17
381,403
222.26M
US$ 10.100B
US$ 178.92
-11.22 -5.90
923,297
51.14M
US$ 9.150B
US$ 92.73
-1.92 -2.03
174,066
69.53M
US$ 6.450B
US$ 33.16
0.82 2.54
1.89M
152.40M
US$ 5.050B
US$ 66.23
-0.36 -0.54
126,816
74.03M
US$ 4.900B
US$ 37.12
-0.98 -2.57
686,997
123.56M
US$ 4.590B
US$ 12.73
-0.36 -2.75
135,992
283.24M
US$ 3.610B
US$ 41.53
-3.08 -6.90
532,410
67.26M
US$ 2.790B
US$ 11.86
-0.78 -6.17
838,659
216.70M
US$ 2.570B
US$ 43.34
-0.24 -0.55
185,972
59.36M
US$ 2.570B
US$ 12.52
-0.11 -0.87
481,239
128.36M
US$ 1.610B
US$ 24.00
-1.07 -4.27
432,200
53.63M
US$ 1.290B
US$ 13.62
-0.66 -4.62
129,605
91.04M
US$ 1.240B
US$ 1.49
-0.05 -2.94
664,144
672.80M
US$ 999.110M
US$ 1.97
-0.10 -4.61
771,483
372.26M
US$ 731.490M
US$ 24.43
-1.72 -6.58
341,596
28.01M
US$ 684.280M
US$ 1.84
-0.17 -8.46
4.57M
294.32M
US$ 541.550M
US$ 17.10
-0.84 -4.68
39,835
30.59M
US$ 523.090M
US$ 35.24
-0.60 -1.67
113,046
14.29M
US$ 503.580M
US$ 16.88
-0.39 -2.26
6,561
23.48M
US$ 396.220M
US$ 2.05
0.12 6.17
19.33M
155.96M
US$ 319.560M
US$ 6.33
0.00 0.00
25,203
32.80M
US$ 207.620M
US$ 1.20
-0.05 -3.63
184,311
145.47M
US$ 173.840M
C$ 0.54
0.00 0.00
0
282.82M
C$ 152.720M
US$ 4.17
-0.05 -1.18
125,988
32.02M
US$ 133.520M
US$ 2.18
-0.16 -6.84
916,713
55.65M
US$ 121.320M
US$ 1.99
-0.01 -0.50
92,236
49.50M
US$ 98.500M
US$ 3.54
-0.10 -2.75
56,261
19.01M
US$ 67.300M
US$ 5.94
0.51 9.39
2,442
10.64M
US$ 63.200M
US$ 0.63
0.009 1.45
17,281
95.97M
US$ 60.460M
US$ 2.12
0.07 3.41
17,572
26.67M
US$ 56.540M
US$ 6.51
0.00 0.00
0
8.53M
US$ 55.530M
US$ 3.13
0.01 0.35
83,416
17.64M
US$ 55.230M
C$ 0.42
0.00 0.00
0
113.40M
C$ 47.060M
US$ 0.67
0.0057 0.86
33,699
52.24M
US$ 35.000M
US$ 0.89
0.09 11.97
162,458
34.10M
US$ 30.180M
US$ 1.12
-0.01 -0.88
2,439
25.04M
US$ 28.040M
US$ 0.78
0.02 2.36
53,746
31.93M
US$ 24.910M
US$ 0.79
-0.03 -3.66
87,839
27.52M
US$ 21.740M
US$ 0.21
-0.02 -8.03
3.79M
101.99M
US$ 20.910M
C$ 0.19
0.00 0.00
0
90.89M
C$ 17.270M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
C$ 0.12
0.00 0.00
0
100.02M
C$ 11.500M
US$ 0.73
-0.03 -3.41
80,880
15.58M
US$ 11.360M
US$ 4.86
0.19 4.07
22,897
2.22M
US$ 10.790M
US$ 0.19
-0.0004 -0.21
536,356
52.29M
US$ 10.090M
US$ 0.59
-0.05 -7.17
21,211
16.67M
US$ 9.900M
C$ 0.17
0.00 0.00
0
59.60M
C$ 9.830M
US$ 6.34
0.34 5.67
18,856
1.48M
US$ 9.380M
US$ 0.90
-1.00 -52.63
453
10.07M
US$ 9.060M
US$ 1.30
-0.20 -13.33
87,208
5.85M
US$ 7.600M
C$ 0.07
0.00 0.00
0
101.29M
C$ 6.580M
US$ 0.29
-0.04 -10.94
316,211
21.04M
US$ 6.000M
US$ 0.36
-0.001 -0.28
54,782
15.37M
US$ 5.530M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 5.72
-0.01 -0.17
970
536,908
US$ 3.070M
US$ 2.74
0.06 2.24
42,024
962,637
US$ 2.640M
US$ 0.78
0.00 0.00
0
3.37M
US$ 2.630M
US$ 0.00
0.00 0.00
0
6.39M
US$ -

Latest News From Diagnostics & Research Stocks


PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially... Read more


Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.ill... Read more


PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million... Read more


Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

CHICAGO / Jan 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision... Read more


DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets

New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK, Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a collaboration with MediOrbis, a multi-specialty... Read more


ICON Issues Financial Guidance for Full Year 2025

Highlights Full year 2025 revenue guidance in the range of $8,050 - $8,650 million; midpoint of $8,350 million representing growth of approximately 1% over full year 2024 revenue guidance midpoint. Full year 2025 adjusted earnings per share* guidance in the range of $13.00 - $15.00; midpoint of $14.00, flat over full year 2024 adjusted earnings per share guidance midpoint. With respect to full year 2024, the company reaffirmed its current guidance of revenue in the range... Read more


Bionano Genomics Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss

OGM uniquely identified a complex chromosomal rearrangement missed by classical cytogenetics, helping clinical researchers apply targeted screening to select the most fit embryos for transfer Following in-vitro fertilization, preimplantation genetic testing and selection of fit embryos, a healthy baby was born to a couple that had previously experienced years of recurrent pregnancy loss SAN DIEGO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq:... Read more


Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference

CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health’s business. “I... Read more


QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

Top-line Results In Line with Expectations; Company Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 SAN DIEGO / Jan 13, 2025 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter... Read more


IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions

RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions. This collaboration between IQVIA... Read more


Illumina and NVIDIA collaborate to decode biology and propel precision health

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development,... Read more


Tempus AI Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

CHICAGO / Jan 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy,... Read more


Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2024 Results

Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated decrease of approximately 25% over Q4 2023 due primarily to discontinuation of clinical service products in 2024 Installed base of optical genome mapping (OGM) systems reached an estimated 371 as of YE 2024, which is an increase of 14% over the 326 installed OGM systems as of YE 2023 Preliminary number of nanochannel array flowcells sold in Q4 2024 expected to... Read more


Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

WALTHAM, Mass. & SAN DIEGO / Jan 13, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow... Read more


Tempus AI Announces Preliminary Fourth Quarter and Full Year 2024 Results

CHICAGO / Jan 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 million, representing approximately 30% growth year-over-year Continued improvement in adjusted... Read more


Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics

BRANFORD, Conn. / Jan 13, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering. Platinum Pro delivers a comprehensive solution for sequencing and analyzing... Read more


Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

WILMINGTON, Mass. / Jan 13, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor... Read more


Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

SAN DIEGO / Jan 13, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the... Read more


Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. / Jan 13, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same... Read more


Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

 Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools... Read more


CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results

Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million BRISBANE, Calif. / Jan 13, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million,... Read more


MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance

IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods. During the fourth quarter,... Read more


Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay,... Read more


Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market

Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company to host conference call... Read more


Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 AUSTIN, Texas / Jan 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter... Read more


Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

Highlighted announcements: Expects total fourth quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023 Plans to launch three new cancer tests in 2025: Cologuard PlusTM, next-generation colorectal cancer screening test, OncodetectTM, molecular... Read more


Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million FRIENDSWOOD, Texas / Jan 12, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide... Read more


Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

WALTHAM, Mass. / Jan 12, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio... Read more


Qiagen to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS Return of up to $300 million – maximum approved by shareholders – set to be completed in late January 2025 Builds on approximately $300 million returned to shareholders in early 2024 as part of commitment to return at least $1 billion through end 2028 VENLO, Netherlands / Jan 12, 2025 / Business... Read more


Exagen Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus... Read more


Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant... Read more


Applied DNA Sciences Completes Buildout of GMP Facility for LineaDNA IVT Templates

Signals Start of New Commercialization Phase for LineaRx Subsidiary Company Negotiating GMP Supply Agreement Company Reaffirms Strategic Restructuring Timeline STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its... Read more


Revvity Announces FDA Clearance for First Automated Free Testosterone Test

WALTHAM, Mass. / Jan 10, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for... Read more


NeoGenomics Announces Chief Executive Officer Succession

Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance FT. MYERS, Fla. / Jan 10, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since... Read more


Neogen Announces Preliminary¹ Second-Quarter 2025 Results

Revenue of $231.3 million. Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share. Adjusted Net Income2 of $24.4 million; $0.11 per diluted share. Adjusted EBITDA2 of $51.4 million. Updating full-year guidance. LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress,... Read more


PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s... Read more


Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). The financial results included in this release pertaining to the fourth quarter and fiscal 2024 are preliminary, unaudited, and subject to final review and adjustment. Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial... Read more


QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets No instrument hardware changes required for upgraded capability thanks to new QIAcuity Software 3.1 update and launch of QIAcuity High Multiplex Probe PCR Kit New QIAcuity digital PCR capabilities helps make lab work more productive and cost-efficient through savings on time, reagents... Read more


Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations. Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and... Read more


Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

CHICAGO / Jan 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately... Read more


Thermo Fisher Scientific’s Olink Platform Selected for World’s Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery WALTHAM, Mass. / Jan 09, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP... Read more


Qiagen secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

New QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions QIAGEN the first to offer both comprehensive and targeted syndromic gastrointestinal panels, giving clinicians unmatched flexibility to optimize diagnostics for individual patients QIAstat-Dx Rise higher-capacity instrument version to be submitted in early 2025 for U.S. regulatory clearance, builds on groundbreaking... Read more


Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening

A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch Regulatory strategy responds to the "urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue Comprehensive filing includes patient acquisition and clinical study plans that validate a projected... Read more


Tempus AI Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict... Read more


Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the release of its latest preprint titled “Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking.” This study highlights the potential of integrating Quantum-Si’s benchtop Platinum® instrument with an innovative protein... Read more


Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived... Read more


23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology

SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world’s leading biomedical research organizations and... Read more


Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of Nature Medicine titled “Proteomic changes upon treatment with semaglutide in individuals with obesity”. Conducted by a team of researchers from Novo Nordisk A/S and collaborators, this seminal paper investigated the effects of semaglutide... Read more


RadNet to Present at the 43rd Annual J.P. Morgan Healthcare Conference January 15th, 2025

LOS ANGELES, Jan. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer and Dr. Gregory Sorensen, Executive Vice President and Chief Science Officer will be presenting... Read more


Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer

Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader, has been named senior vice president and chief quality and regulatory affairs officer. Ms. Brott is responsible for leading... Read more